Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus Apatinib
in the treatment of advanced non-squamous NSCLC previously treated with first-line
immunotherapy